FDA panel suggests longer monkey trials of AAV gene therapies


An FDA advisory committee said adeno-associated virus vector gene therapies should undergo long-term testing in animals to uncover any liver toxicity risk. AAV gene therapies for spinal muscular atrophy and X-linked myotubular myopath have been associated with acute liver failure in clinical trials, and following macaques for longer could reveal more about the mechanisms of acute and long-term effects, says Caroline Zeiss, a researcher at Yale University's Department of Comparative Medicine.

Full story:

FBR SmartBrief

Biomedical research news.

FBR SmartBrief is a FREE, weekly e-mail newsletter. By providing the latest need-to-know industry news and information, FBR SmartBrief saves you time and keeps you smart.